Selected article for: "chronic condition and HIV people"
Author: Castelli, Valeria; Lombardi, Andrea; Palomba, Emanuele; Bozzi, Giorgio; Ungaro, Riccardo; Alagna, Laura; Mangioni, Davide; Muscatello, Antonio; Bandera, Alessandra; Gori, Andrea
Title: Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies
  • Cord-id: 1r5bzyau
  • Document date: 2021_8_27
    • ID: 1r5bzyau
    Snippet: Immune checkpoint inhibitors (ICIs) are reshaping the landscape of cancer treatment, redefining the prognosis of several tumors. They act by restoring the cytotoxic activity of tumor-specific T lymphocytes that are in a condition of immune exhaustion. The same condition has been widely described in chronic HIV infection. In this review, we dissect the role of ICIs in people living with HIV/AIDS (PLWHIV). First, we provide an overview of the immunologic scenario. Second, we discuss the possible u
    Document: Immune checkpoint inhibitors (ICIs) are reshaping the landscape of cancer treatment, redefining the prognosis of several tumors. They act by restoring the cytotoxic activity of tumor-specific T lymphocytes that are in a condition of immune exhaustion. The same condition has been widely described in chronic HIV infection. In this review, we dissect the role of ICIs in people living with HIV/AIDS (PLWHIV). First, we provide an overview of the immunologic scenario. Second, we discuss the possible use of ICIs as adjuvant treatment of HIV to achieve elimination of the viral reservoir. Third, we examine the influence of HIV infection on ICI safety and effectiveness. Finally, we describe how the administration of ICIs impacts opportunistic infections.

    Search related documents:
    Co phrase search for related documents
    • abdominal infection and active infection: 1, 2, 3, 4
    • abdominal infection and lung infection: 1, 2, 3
    • action mechanism and adjuvant treatment: 1, 2
    • action mechanism and lung adenocarcinoma: 1
    • action mechanism and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • action mechanism and lung carcinoma: 1, 2
    • action mechanism and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • active infection and adjuvant treatment: 1
    • active infection and ltbi latent tuberculosis: 1, 2, 3, 4, 5, 6, 7, 8
    • active infection and ltbi latent tuberculosis reactivation: 1, 2
    • active infection and ltbi reactivation: 1, 2, 3, 4, 5
    • active infection and lung cancer: 1, 2, 3, 4, 5, 6, 7
    • active infection and lung carcinoma: 1
    • active infection and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • active infection patient and lung cancer: 1
    • active infection patient and lung infection: 1, 2
    • adjuvant treatment and lung adenocarcinoma: 1
    • adjuvant treatment and lung cancer: 1, 2, 3, 4, 5, 6